Stephen B. Keysar

Stephen B. Keysar

Auto-generated profile, based on publicly available information

Stephen B. Keysar

Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2020 in Molecular Cancer Research
Verified
Journal Article
Open access
PDF file
JMJ. Jason Morton
J. Jason Morton
NANathaniel Alzofon
Nathaniel Alzofon
SKStephen B. Keysar
Stephen B. Keysar
TCTugs-Saikhan Chimed
Tugs-Saikhan Chimed
JRJulie Reisinger
Julie Reisinger
AJAntonio Jimeno
Antonio Jimeno
Resistance to immunotherapy is a significant challenge, and the scarcity of human models hinders the identification of the underlying mechanisms. To address this limitation, we constructed an autologous humanized mouse (aHM) model with hematopoietic stem and progenitor cells (HSPC) and tumors from 2 melanoma patients progressing to immunotherapy. Unlike mismatched humanized mouse (mHM) models, generated from cord blood–derived HSPCs and tumors from different donors, the aHM recapitulates a patient-specific tumor microenvironment (TME). When patient tumors were implanted on aHM, mHM, and NOD/SCID/IL2rg−/− (NSG) cohorts, tumors appeared earlier and grew faster on NSG and mHM cohorts. We observed that immune cells differentiating in the aHM were relatively more capable of circulating peripherally, invading into tumors and interacting with the TME. A heterologous, human leukocyte antigen (HLA-A) matched cohort also yielded slower growing tumors than non–HLA-matched mHM, indicating that a less permissive immune environment inhibits tumor progression. When the aHM, mHM, and NSG cohorts were treated with immunotherapies mirroring what the originating patients received, tumor growth in the aHM accelerated, similar to the progression observed in the patients. This rapid growth was associated with decreased immune cell infiltration, reduced interferon gamma (IFNγ)–related gene expression, and a reduction in STAT3 phosphorylation, events that were replicated in vitro using tumor-derived cell lines. Implications: Engrafted adult HSPCs give rise to more tumor infiltrative immune cells, increased HLA matching leads to slower tumor initiation and growth, and continuing immunotherapy past progression can paradoxically lead to increased growth.

20 May 2010 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
SKS. Keysar
S. Keysar
RAR. Anderson
R. Anderson
STS. Takimoto
S. Takimoto
ATAi-hua Tan
Ai-hua Tan
IDIgor V. Deyneko
Igor V. Deyneko
AJA. Jimeno
A. Jimeno
5558 Background: A DPTM of HNSCC was established to optimally test novel therapies and the role of cancer stem cells (CSC) in relapses after therapy. This study examines the role of the Hedgehog pathway (HhP) in HNSCC and the effect of the smoothened (SMO) inhibitor IPI-926 alone and combined with the EGFR inhibitor cetuximab (Cet). Methods: Mouse models generated from implanted HNSCC surgical cases were optimized for a combination of factors (e.g. mouse strain, tumor location) yielding the most similar tumor to the parental cancer using morphologic, stroma invasion and gene expression analysis. Results: Tumor fragments from 25 cases were implanted with a 65% engraftment rate. An unbiased gene analysis comparing pathways enriched in 42 HNSCC and 14 head and neck normal tissues showed enrichment for the HhP in the cancers. IHC staining for the ligand sonic hedgehog (SHH) of a tissue array of 60 HNSCC and 20 normal tissues indicated that 65% were positive (++) or very positive (+++) and only 35% of the cancers were negative or faint (+), while 78% of normal tissues were negative for SHH. Samples from 3 DPTM and 3 cell line-derived xenografts were positive for SHH. Four DPTMs were treated in vivo with Cet, IPI-926, and the combination. IPI-926 had activity (T/C <40%) in two cases, and both Cet and the combination induced regressions in three. Whereas in all cases Cet-treated tumors re-grew 4-8 weeks post-therapy, combination- treated mice were relapse-free 3 months post-therapy. To test if Cet leads to CSC accumulation, putative CSC markers were measured by flow cytometry. CD24/44 and CD24/ALDH cells accumulated in Cet-treated tumors but decreased in combination-treated tumors. Implanted CD24/44 and CD24/ALDH positive cells generated tumors at a higher rate than negative cells despite a 100-fold cell dilution. These subgroups expressed SMO and GLI1 genes 200-fold and 700-fold higher than negative cells, respectively. Conclusions: The HhP is activated in HNSCC, with over-expression seen in the CSC subpopulation, where data suggests autologous signaling. When combined with Cet, HhP inhibition with IPI-926 diminishes CSC and prevents tumor relapse in a DPTM of HNSCC.

1 November 2025 in Cancer Research Communications
Verified
Journal Article
Open access
JMJ. Jason Morton
J. Jason Morton
SRStephan A. Ramos
Stephan A. Ramos
NANathaniel Alzofon
Nathaniel Alzofon
SKStephen B. Keysar
Stephen B. Keysar
LALucas H. Armitage
Lucas H. Armitage
AJAntonio Jimeno
Antonio Jimeno
A fundamental limitation of HLA-A matched humanized mice (mHM), generated with donor hematopoietic stem and progenitor cells and bearing patient-derived xenografts, is that the fidelity of the interaction between the immune system and implanted tumors is limited by lack of thymic T-cell education. We created a model with patient-matched thymic and tumor tissue by using patient peripheral blood mononuclear cells reprogrammed into induced pluripotent stem cells to generate stem cell–derived thymic organoids (sTOs). When implanted in thymectomized mHM, which were subsequently engrafted with patient melanoma tissue (autologous, or mHMTA), sTOs expressed thymic tissue markers EPCAM, KRT5, and KRT8 and contained developing double-positive T cells. mHMTA had more activated HLA-DR+ T cells in their spleens. Tumor growth in mHMTA was significantly slower compared with mHM, and both tumor volume and viable melanoma content were significantly decreased in mHMTA. This was associated with an increase of intratumoral activated T cells in mHMTA. Whole-exome sequencing followed by intratumoral heterogeneity analysis identified seven candidate neoantigens that were selected against in the mHMTA model, suggesting more effective identification and T cell–driven tumor clearance. This study shows the feasibility of generating patient-specific, thymus-bearing mice and provides a promising new tool in immunology and immunotherapy development. Significance: A humanized mouse xenograft model, in which T cells are educated in a patient-derived implanted thymic organoid autologous to the tumor, provides a more faithful and complete environment to study cancer immunity.



24 November 2025
Verified
Other
Open access
JMJ. Jason Morton
J. Jason Morton
SRStephan A. Ramos
Stephan A. Ramos
NANathaniel Alzofon
Nathaniel Alzofon
SKStephen B. Keysar
Stephen B. Keysar
LALucas H. Armitage
Lucas H. Armitage
AJAntonio Jimeno
Antonio Jimeno
Examination of T-cell development and activity in the mHMTA. A, Representative cytometry of the human CD45+ cells and HSPCs present in mHM and mHMTA bone marrow. B, Comparison of the average percentage of human CD45+ cells and CD34+ HSPCs within this CD45+ cell population within mHM and mHMTA bone marrow (P = 0.118 and 0.379, respectively, Wilcoxon rank-sum test). C, Comparison of peripheral human CD45+ lymphocytes in mHM and mHMTA (P = 0.728, Wilcoxon rank-sum test) and of CD19+ B cells in mHM and mHMTA (0.224, Wilcoxon rank-sum test). D, Cytometric analysis and a comparison of human CD45+ cells, as well as T-cell and B-cell populations, found in the spleens of mHM and mHMTA. E, Comparison of the average human CD45+ cell populations, human T cells, and human B cells on mHM and mHMTA spleens (P = 0.844, 0.450, and 0.646, Wilcoxon rank-sum test, respectively). F, IFNγ expression was detected in the spleen of both mHM and mHMTA (P < 0.005). G, Gating and representative cytometry of T cells in mHM and mHMTA show relative populations used to analyze T-cell activation. Purple boxes in the first panels show the T-cell populations gated in the remaining scatter plots. The red boxes show the CD8+ T-cell populations gated for subsequent analysis. H, Representative cytometry of the CD8+ T cells, gated from the red boxes in the previous panel. I, Comparisons of the ratio of HLA-DR + PD1– T cells with all HLA-DR+ T cells shows an increasingly activated T-cell population in mHMTA (P = 0.0207, two-group t test) and a nonsignificantly increased population of CD4+ T cells. J, Comparison of the HLA-DR + PD1– population with the total HLA-DR+ T-cell population among CD8+ T cells also reveals a trend toward increased activation in mHMTA. P values: *, ≤0.05.